5-Hydroxymethylcytosine Loss in Conjunctival Melanoma
Aims: Conjunctival and cutaneous melanoma partially share similar clinical and molecular backgrounds. As 5-hydroxymethylcytosine (5-hmC) loss has been demonstrated in cutaneous melanoma, we decided to assess if similar changes were occurring in conjunctival melanoma. Methods: 5-methylcytosine (5-mC)...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Dermatopathology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2296-3529/8/2/23 |
| _version_ | 1797531331381428224 |
|---|---|
| author | Alexandre Stahl Nicolo Riggi Katya Nardou Michael Nicolas Gurkan Kaya Alexandre Moulin |
| author_facet | Alexandre Stahl Nicolo Riggi Katya Nardou Michael Nicolas Gurkan Kaya Alexandre Moulin |
| author_sort | Alexandre Stahl |
| collection | DOAJ |
| description | Aims: Conjunctival and cutaneous melanoma partially share similar clinical and molecular backgrounds. As 5-hydroxymethylcytosine (5-hmC) loss has been demonstrated in cutaneous melanoma, we decided to assess if similar changes were occurring in conjunctival melanoma. Methods: 5-methylcytosine (5-mC), 5-hmC and TET2 were respectively identified by immunohistochemistry and RNA ISH in 40 conjunctival nevi and 37 conjunctival melanomas. Clinicopathological correlations were established. Results: 5-mC, TET2 and 5-hmC were respectively identified in 67.5%, 95% and 100% of conjunctival nevi and in 81.1%, 35.1% and 54% of conjunctival melanomas. A significant 5-hmC and TET2 loss was identified in conjunctival melanoma comparing to nevus, as well as a significant correlation between TET2 and 5-hmC expression. In the melanomas, 5-hmC expression was only significantly associated with local lymphatic invasion, but not with other clinicopathological parameters. There was a correlation between TET2 expression and the localization of the tumors. 5-mC expression was not associated with any clinicopathological parameters. Conclusions: We identified a significant 5-hmC loss in conjunctival melanoma similar to cutaneous melanoma. This loss may possibly be attributed to TET2 loss or IDH1 mutations. 5-hmC loss in conjunctival melanoma may help in the differential diagnosis between atypical conjunctival nevus and conjunctival melanoma. |
| first_indexed | 2024-03-10T10:42:15Z |
| format | Article |
| id | doaj.art-b3fc3f79a98e461d9a02b6c98048e626 |
| institution | Directory Open Access Journal |
| issn | 2296-3529 |
| language | English |
| last_indexed | 2024-03-10T10:42:15Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Dermatopathology |
| spelling | doaj.art-b3fc3f79a98e461d9a02b6c98048e6262023-11-21T22:54:44ZengMDPI AGDermatopathology2296-35292021-06-018217618410.3390/dermatopathology80200235-Hydroxymethylcytosine Loss in Conjunctival MelanomaAlexandre Stahl0Nicolo Riggi1Katya Nardou2Michael Nicolas3Gurkan Kaya4Alexandre Moulin5Jules-Gonin Eye Hospital, Lausanne University, 1004 Lausanne, SwitzerlandExperimental Pathology, University Hospital of Lausanne (CHUV), 1011 Lausanne, SwitzerlandJules-Gonin Eye Hospital, Lausanne University, 1004 Lausanne, SwitzerlandJules-Gonin Eye Hospital, Lausanne University, 1004 Lausanne, SwitzerlandDermatopathology Unit, Dermatology and Clinical Pathology Departments, University Hospitals of Geneva, 1205 Geneva, SwitzerlandJules-Gonin Eye Hospital, Lausanne University, 1004 Lausanne, SwitzerlandAims: Conjunctival and cutaneous melanoma partially share similar clinical and molecular backgrounds. As 5-hydroxymethylcytosine (5-hmC) loss has been demonstrated in cutaneous melanoma, we decided to assess if similar changes were occurring in conjunctival melanoma. Methods: 5-methylcytosine (5-mC), 5-hmC and TET2 were respectively identified by immunohistochemistry and RNA ISH in 40 conjunctival nevi and 37 conjunctival melanomas. Clinicopathological correlations were established. Results: 5-mC, TET2 and 5-hmC were respectively identified in 67.5%, 95% and 100% of conjunctival nevi and in 81.1%, 35.1% and 54% of conjunctival melanomas. A significant 5-hmC and TET2 loss was identified in conjunctival melanoma comparing to nevus, as well as a significant correlation between TET2 and 5-hmC expression. In the melanomas, 5-hmC expression was only significantly associated with local lymphatic invasion, but not with other clinicopathological parameters. There was a correlation between TET2 expression and the localization of the tumors. 5-mC expression was not associated with any clinicopathological parameters. Conclusions: We identified a significant 5-hmC loss in conjunctival melanoma similar to cutaneous melanoma. This loss may possibly be attributed to TET2 loss or IDH1 mutations. 5-hmC loss in conjunctival melanoma may help in the differential diagnosis between atypical conjunctival nevus and conjunctival melanoma.https://www.mdpi.com/2296-3529/8/2/23conjunctival melanomaepigenetics5-hydroxymethylcytosine5-methylcytosineTET2 |
| spellingShingle | Alexandre Stahl Nicolo Riggi Katya Nardou Michael Nicolas Gurkan Kaya Alexandre Moulin 5-Hydroxymethylcytosine Loss in Conjunctival Melanoma Dermatopathology conjunctival melanoma epigenetics 5-hydroxymethylcytosine 5-methylcytosine TET2 |
| title | 5-Hydroxymethylcytosine Loss in Conjunctival Melanoma |
| title_full | 5-Hydroxymethylcytosine Loss in Conjunctival Melanoma |
| title_fullStr | 5-Hydroxymethylcytosine Loss in Conjunctival Melanoma |
| title_full_unstemmed | 5-Hydroxymethylcytosine Loss in Conjunctival Melanoma |
| title_short | 5-Hydroxymethylcytosine Loss in Conjunctival Melanoma |
| title_sort | 5 hydroxymethylcytosine loss in conjunctival melanoma |
| topic | conjunctival melanoma epigenetics 5-hydroxymethylcytosine 5-methylcytosine TET2 |
| url | https://www.mdpi.com/2296-3529/8/2/23 |
| work_keys_str_mv | AT alexandrestahl 5hydroxymethylcytosinelossinconjunctivalmelanoma AT nicoloriggi 5hydroxymethylcytosinelossinconjunctivalmelanoma AT katyanardou 5hydroxymethylcytosinelossinconjunctivalmelanoma AT michaelnicolas 5hydroxymethylcytosinelossinconjunctivalmelanoma AT gurkankaya 5hydroxymethylcytosinelossinconjunctivalmelanoma AT alexandremoulin 5hydroxymethylcytosinelossinconjunctivalmelanoma |